BFS
ACAD icon

Bare Financial Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Bare Financial Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29K Sell
103
-139
-57% -$3.32K ﹤0.01% 939
2025
Q4 		$6.46K Buy
242
+190
+365% +$4.54K ﹤0.01% 431
2025
Q3 		$1.11K Buy
52
+21
+68% +$497 ﹤0.01% 988
2025
Q2 		$669 Buy
+31
New +$576 ﹤0.01% 1038

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bare Financial Services's ACAD Position: Q1 2026 in Review

Bare Financial Services reduced its Acadia Pharmaceuticals (ACAD) stake by 57% in Q1 2026, selling an estimated $3.32K and leaving 103 shares worth $2.29K. The position accounts for ﹤0.01% of the portfolio, ranked #939.

Bare Financial Services first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. The position peaked at $6.46K in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Bare Financial Services held 103 shares of Acadia Pharmaceuticals worth $2.29K as of Q1 2026.
  • Bare Financial Services sold 139 Acadia Pharmaceuticals shares in Q1 2026, an estimated $3.32K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #939 holding.
  • Bare Financial Services first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Bare Financial Services's Acadia Pharmaceuticals position peaked at $6.46K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.